New hope for bile duct cancer patients: expanded access to targeted drug futibatinib

NCT ID NCT04507503

APPROVED_FOR_MARKETING Disease control Sponsor: Taiho Oncology, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This program provides futibatinib (TAS-120) to adults with advanced bile duct cancer that has a specific FGFR2 gene change and who have no other treatment options. Participants take one 20 mg pill daily. The goal is to give access to this drug while it is being studied further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Futibatinib (TAS-120)
What this could lead to: If it works, this could offer a treatment option for people with advanced bile duct cancer who have a specific gene change and have run out of standard therapies.
What could go wrong: This is an expanded access program, not a formal trial, so it provides access rather than proving effectiveness. The drug may not work for everyone and can have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CHOLANGIOCARCINOMA

Contacts and locations

Locations

Advent Health Orlando

Orlando, Florida, 32804, United States
Aurora Cancer care

Grafton, Wisconsin, 53024, United States
Banner MD Anderson

Gilbert, Arizona, 85234, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
MD Anderson

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mount Sinai Center of Florida

Miami Beach, Florida, 33140, United States
Providence Portland Medical Center

Portland, Oregon, 97213, United States
Seattle Cancer Care Alliance

Seattle, Washington, 98109, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21231, United States
UCLA Division of Hematology-Oncology

Santa Monica, California, 90404, United States
University of California, San Francisco (UCSF)

San Francisco, California, 94143, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Kansas Cancer Center

Lee's Summit, Missouri, 64064, United States
Utah Cancer Specialists

Salt Lake City, Utah, 84106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.